A recent workshop hosted by the Global Alliance for Patient Access (GAfPA) allowed patient advocates from across Europe’s Nordic region to consider biosimilar policies and discuss a topic of growing international interest: switching from a biologic to a biosimilar medicine.
The workshop, held on October 5-6, 2016 in Copenhagen, drew seven different patient advocacy groups from Denmark, Sweden and Iceland. Representatives came from the Nordic Rheuma Council, the Swedish Rheumatology Association, the Danish Crohn’s and Colitis Association, the Danish Hidradenitis Suppurativa Association and the Danish Psoriasis Organisation, as well as the Icelandic League Against Rheumatism, and the Icelandic Crohn’s and Colitis Organisation.
Click here to read the full report in English!
You can also read the report in Finnish, here.